Published July 19, 2024
| Version v1
Journal article
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review
Contributors
Others:
- Hospital Quirónsalud Bizkaia [Bilbao]
- Charité - UniversitätsMedizin = Berlin University Medicine
- Freie Universität Berlin
- Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin (HU Berlin)
- Humanitas University [Milan] (Hunimed)
- CHU Montpellier = Montpellier University Hospital ; Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Institut Desbrest d'Epidémiologie et de Santé Publique (IDESP) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Médecine de précision par intégration de données et inférence causale (PREMEDICAL) ; Centre Inria d'Université Côte d'Azur (CRISAM) ; Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest d'Epidémiologie et de Santé Publique (IDESP) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Universidad Católica De Salta (Ucasal)
- ALAS Medical Institute
- University of California [San Diego] (UC San Diego) ; University of California (UC)
- SANOFI Recherche
- Johns Hopkins University School of Medicine [Baltimore]
- Universidade Tecnológica Federal do Paraná = Federal Technological University of Paraná [Curitiba, Brésil] (UTFPR)
- University College of London [London] (UCL)
- Sanofi
Description
Fexofenadine is a second-generation inverse agonist of H1-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood-brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04920792
- URN
- urn:oai:HAL:hal-04920792v1
Origin repository
- Origin repository
- UNICA